The recent expansion of mpox in Africa is characterized by a dramatic increase in zoonotic transmission (clade Ia) and the emergence of a new clade Ib that is transmitted from human to human by close contact. Clade Ia does not pose a threat in areas without zoonotic reservoirs. But clade Ib may spread widely, as did clade IIb which has spread globally since 2022 among men who have sex with men. It is not clear whether controlling clade Ib will be more difficult than clade IIb. The population at risk potentially counts 100 million but only a million vaccine doses are expected in the next year. Surveillance is needed with exhaustive case detection, polymerase chain reaction confirmation, clade determination, and about severe illness. Such data is needed to identify routes of transmission and core transmitters, such as sex workers. Health care workers are vaccinated to ensure their protection, but this will not curb mpox transmission. With the recent inequitable distribution of COVID-19 vaccines in mind, it is a global responsibility to ensure that low-income nations in the mpox epicenter have meaningful access to vaccines. Vaccination serves not only to reduce mortality in children but limit the risk of future mpox variants emerging that may spread in human populations globally.
Journal Article > ReviewFull Text
Int J Infect Dis. 1 April 2025; Volume 153; 107373.; DOI:10.1016/j.ijid.2024.107373
Petersen E, Hvid U, Tomori O, Pedersen AG, Wallinga J, et al.
Int J Infect Dis. 1 April 2025; Volume 153; 107373.; DOI:10.1016/j.ijid.2024.107373
Journal Article > ResearchFull Text
Int J Infect Dis. 1 February 2020; Volume 92; DOI:10.1016/j.ijid.2020.01.042
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, et al.
Int J Infect Dis. 1 February 2020; Volume 92; DOI:10.1016/j.ijid.2020.01.042
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
Journal Article > CommentaryFull Text
Nat Rev Drug Discov. 17 July 2015; Volume 14 (Issue 8); DOI:10.1038/nrd4696
Zumla A, Chakaya JM, Hoelscher M, Ntoumi F, Rustomjee R, et al.
Nat Rev Drug Discov. 17 July 2015; Volume 14 (Issue 8); DOI:10.1038/nrd4696